<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01061320</url>
  </required_header>
  <id_info>
    <org_study_id>MTU-I-1-53/52</org_study_id>
    <nct_id>NCT01061320</nct_id>
  </id_info>
  <brief_title>Efficacy of Alpha Tocopherol for Prevention of Contrast-induced Nephropathy in Chronic Kidney Disease (CKD) Patients</brief_title>
  <official_title>Efficacy of Alpha Tocopherol and New Biomarker (Urine NGAL) for Prevention and Early Diagnosis of Contrast-induced Nephropathy in CKD Patients Undergoing Elective Coronary Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thammasat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thammasat University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of alpha tocopherol for prevention
      contrast-induced nephropathy in CKD patients undergoing elective coronary procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contrast-induced nephropathy (CIN) increases the likelihood of patient morbidity and
      mortality following coronary procedures. Contrast agents cause an acute deterioration in
      renal function via the generation of reactive oxygen species. Vitamin E (alpha tocopherol)was
      demonstrated to be anti-oxidant and anti-inflammation. The present study was designed to
      evaluate the administration of antioxidant vitamin E (alpha tocopherol) as a means of
      preventing CIN in these patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end-point of this study is the development of CIN in placebo group compared with alpha tocopherol group.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary end-point of this study is compare urine NGAL level in CIN patients between both groups.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <arm_group>
    <arm_group_label>alpha tocopherol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha tocopherol</intervention_name>
    <description>The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.</description>
    <arm_group_label>alpha tocopherol</arm_group_label>
    <other_name>Bio-E-vitamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>jelly</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  serum creatinine levels &gt; 1.2 mg/dL and baseline creatinine clearance levels &lt; 60
             mL/min (as measured in their most recent sample,drawn within 2 months prior to the
             beginning of the study)

        Exclusion Criteria:

          -  patients with acute kidney injury

          -  end stage renal disease (requiring dialysis)

          -  unstable renal function (as evidenced by a change in serum creatinine of &gt; 0.5 mg/dL,
             or &gt; 25%, within 14 days prior to the study)

          -  allergy to any of the contrast agents

          -  mechanical ventilation

          -  suffered from congestive heart failure, cardiogenic shock or emergent angiography.

          -  receiving NAC, mannitol, diuretics, theophylline, dopamine, vitamin E or contrast
             agents within 14 days before the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adis Tasanarong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Thammasat University (Rangsit Campus)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adis Tasanarong</name>
      <address>
        <city>Khlong Luang</city>
        <state>Pathumtani</state>
        <zip>12121</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.nephrothai.org/</url>
    <description>The Nephrology Society of Thailand</description>
  </link>
  <link>
    <url>http://toxnet.nlm.nih.gov</url>
    <description>Toxicology data network</description>
  </link>
  <results_reference>
    <citation>Tasanarong A, Piyayotai D, Thitiarchakul S. Protection of radiocontrast induced nephropathy by vitamin E (alpha tocopherol): a randomized controlled pilot study. J Med Assoc Thai. 2009 Oct;92(10):1273-81.</citation>
    <PMID>19845233</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2010</study_first_submitted>
  <study_first_submitted_qc>February 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2010</study_first_posted>
  <last_update_submitted>February 2, 2010</last_update_submitted>
  <last_update_submitted_qc>February 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Adis Tasanarong</name_title>
    <organization>Faculty of Medicine, Thammasat University (Rangsit Campus)</organization>
  </responsible_party>
  <keyword>Alpha-Tocopherol (Vitamin E)</keyword>
  <keyword>Contrast induced nephropathy</keyword>
  <keyword>Chronic kidney disease</keyword>
  <keyword>Coronary procedures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

